Table 2.

Mean baseline and follow-up GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months (n = 120)

Patient-reported outcome measure	Follow-up (months)	Mean ± SD	P-value compared to previous follow-up period	P-value compared to baseline
GAD-7	Baseline	13.87 ± 0.50
	1	9.51 ± 0.55	<0.001
	3	9.717 ± 0.57	1.000	<0.001
	6	9.97 ± 0.60	1.000	<0.001
	12	11.12 ± 0.60	0.129	<0.001
SQS	Baseline	3.77 ± 0.21
	1	5.64 ± 0.23	<0.001
	3	5.50 ± 0.24	1.000	<0.001
	6	4.99 ± 0.27	0.071	<0.001
	12	4.73 ± 0.26	1.000	<0.001
EQ-5D-5L mobility	Baseline	1.50 ± 0.08
	1	1.43 ± 0.08	1.000
	3	1.46 ± 0.08	1.000	1.000
	6	1.52 ± 0.08	1.000	1.000
	12	1.50 ± 0.08	1.000	1.000
EQ-5D-5L self-care	Baseline	1.51 ± 0.09
	1	1.47 ± 0.09	1.000
	3	1.45 ± 0.08	1.000	1.000
	6	1.54 ± 0.09	0.337	1.000
	12	1.53 ± 0.09	1.000	1.000
EQ-5D-5L usual activities	Baseline	2.33 ± 0.12
	1	2.06 ± 0.11	0.039
	3	1.98 ± 0.11	1.000	0.007
	6	2.15 ± 0.11	0.194	0.399
	12	2.13 ± 0.11	1.000	0.141
EQ-5D-5L pain and discomfort	Baseline	2.13 ± 0.11
	1	1.83 ± 0.09	0.001
	3	1.89 ± 0.10	1.000	0.015
	6	1.89 ± 0.10	1.000	0.002
	12	1.98 ± 0.10	0.858	0.074
EQ-5D-5L anxiety and depression	Baseline	3.43 ± 0.10
	1	2.89 ± 0.10	<0.001
	3	2.94 ± 0.11	1.000	<0.001
	6	2.94 ± 0.11	1.000	<0.001
	12	3.15 ± 0.10	0.180	0.007
EQ-5D-5L index value	Baseline	0.53 ± 0.03
	1	0.64 ± 0.03	<0.001
	3	0.63 ± 0.03	1.000	<0.001
	6	0.61 ± 0.03	1.000	<0.001
	12	0.58 ± 0.03	0.848	0.006
PGIC	1	5.29 ± 0.17
	3	5.55 ± 0.13	0.223	-
	6	5.42 ± 0.16	1.000	-
	12	5.59 ± 0.15	1.000	-